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Abstract 
Primary mucosa-associated lymphoid tissue
(MALT) lymphoma of the prostate is a rare dis-
ease that characteristically follows an indolent
course. It is believed that infection or chronic
inflammation  may  be  triggers  for  malignant
transformation  in  the  prostate,  but  it  is  of
unknown  etiology.  Reports  of  MALT  lymph  -
omas of the prostate with other concurrent pri-
mary prostate cancers are even more limited.
We present the unique case of a 67-year-old
male with concurrent adenocarcinoma of the
prostate and primary MALT lymphoma of the
prostate. The patient was treated with stand  -
ard  therapy  for  prostate  adenocarcinoma,
which would also treat a primary MALT lymph  -
oma. He has been disease-free for over one
year for both his primary malignancies. This
case confirms that MALT lymphoma can arise
concurrently  with  adenocarcinoma  of  the
prostate.   
Introduction
In  1983,  Issacson  and  Wright  identified  a
variant  of  B-cell  lymphoma  in  the  gastro -
intestinal tract that they defined as malignant
lymphoma of mucosa-associated lymphoid tis-
sue  (MALT).
1 Marginal  cell  lymphomas  of
MALT, nodal, and splenic origins were subse-
quently included in the 1994 REAL and 1998
WHO classifications.
2,3 MALT lymphoma is usu-
ally indolent, but may transform into aggres-
sive large cell lymphomas. It constitutes 8-10%
of non-Hodgkin’s lymphomas, with most cases
being localized at presentation and remaining
so for long periods of time. They are usually
highly  responsive  to  local  radiation  therapy,
with 30 Gy to involved nodal or extranodal sites
yielding a control rate close to 100% and the
chance of long-term cure in approximately 75%
of patients.
4-8 Relapses tend to occur at other
extranodal sites where MALT lymphomas usu-
ally occur, or in a nonirradiated contralateral
paired organ.  
The literature on MALT lymphomas of the
prostate is very limited. MALT of the prostate
may be the result of disseminated or primary
disease.
9 One case report describes a patient
with an indolent course of salivary gland dis-
ease that later disseminated to the renal sinus-
es and prostate.
10 Accordingly, MALT lymphoma
in the prostate should be considered in the dif-
ferential  diagnoses  for  lymphoma  patients
with  systemic  disease  who  present  with
obstructive urinary symptoms.
11 There are only
seven case reports of primary prostatic MALT
lymphoma.
10,12-17 Typically, the patient presents
with  symptoms  of  urinary  obstruction,  and
workup for what is presumed to be another
prostatic process returns a diagnosis of MALT
lymphoma  in  the  resection  specimen.
10,14-16,18
Treatment can range from radiation therapy,
with external beam to 44 Gy over 22 fractions,
13
to chemotherapy,
16 to transurethral resection
alone.
14,15 Regardless  of  the  presentation  or
treatment used, the disease course is typically
indolent.
10,13,15-17 In  one  case  of  recurrence,  a
man who had been treated for benign prostat-
ic hyperplasia with atypical lymphoid infiltra-
tion presented seven years later with a diagno-
sis of relapsed MALT lymphoma after a newer,
more detailed analysis had been conducted on
the initial and relapsed lesions.
19 The disease
had not been aggressive, as the patient pre-
sented  with  stage  IA  disease  at  the  time  of
relapse  and  remained  disease-free  for  two
years after the second transurethral resection.  
Concurrent  prostatic  adenocarcinoma  and
lymphoma of the prostate is rare, but usually
tends to be with B-cell lymphomas.
11 There is
one case report of a prostatic adenocarcinoma
and  concurrent  chronic  lymphocytic  lymph  -
oma.
18 The  patient  presented  with  urinary
obstruction, hematuria, and a PSA of 46 ng/mL,
and  prostatectomy  showed  disease  in  both
lobes as well as nodes.
Case Report
We report on an unusual case of a patient
who had concurrent primary MALT lymphoma
of  the  prostate  and  adenocarcinoma  of  the
prostate. A 67-year-old Hispanic man present-
ed  with  urinary  frequency  and  nocturia.  He
had  no  history  of  acute  prostatitis,  chronic
pros  tatitis, or Helicobacter pylori (H. pylori)
infection, and the urine culture was negative.
The physical examination was unremarkable.
He had no palpable nodules on the digital rec-
tal examination. Laboratory values revealed a
PSA level of 7.0 ng/mL, which had increased
from 2.8 ng/mL over a one-year time frame.
The  biopsy  revealed  adenocarcinoma  of  the
prostate,  with  a  Gleason  Score  of  3+3.  The
patient then underwent definitive therapy for
his prostate cancer with a radical prostatec  -
tomy.  Pathological  results  from  his  surgery
returned a diagnosis of adenocarcinoma of the
prostate with a pathological stage of pT2cN0.
However, his Gleason score was upstaged to
3+5 with margin status unassessable second-
ary to surgical specimen fragmentation.
Microscopically, the sections of the prostate
showed  an  extensive  lymphoid  infiltrate
(Figure  1)  besides  a  carcinoma,  which  was
present  in  a  different  area,  mostly  at  the
prostate apex. Figure 2 shows the adenocarcin  -
oma of the prostate, Gleason score 3+5. The
lymphoid  infiltrate  showed  monomorphic,
small  lymphoid  cells  with  small  follicles  in
multi  focal areas. The interfollicular areas were
expanded and showed a diffuse infiltrate by
small  lymphoid  cells,  which  had  round  to
irregu  lar nuclear membranes and scanty cyto-
plasm.  Rare  lymphoepithelial  lesions  were
seen in the specimen (Figure 3). This may be
characteristic for MALT of the prostate as this
was also noted by Li et al.
19 The pattern of this
Correspondence: Michael S. Eaton, 1441 Eastlake
Road,  Norris  Cancer  Center,  Department  of
Radiation Oncology, Los Angeles CA, 90033, USA.
E-mail:  michaese@usc.edu  or  eaton.michael@
gmail.com
Key  words:  MALT,  prostate  cancer,  prostate 
lymphoma.
Contributions: JK and ME contributed equally to,
authored, and revised this manuscript; ME was
the treating resident physician for this case; JK
did  the  primary  literature  review;  YM  was  the
attending pathologist and completed all the slide
preparations, immunohistochemical stains, and
pathological  diagnosis;  OS  was  the  treating
attending  physician  for  this  case;  OS  and  PK
offered criticism and advice for this manuscript. 
Conflict of interest: the authors report no con-
flicts of interest.
Received for publication: 25 May 2010.
Revision received: 6 August 2010.
Accepted for publication: 9 August 2010.
This work is licensed under a Creative Commons
Attribution 3.0 License (by-nc 3.0).
©Copyright J.J. Kang et al., 2010
Licensee PAGEPress, Italy
Rare Tumors 2010; 2:e54
doi:10.4081/rt.2010.e54[Rare Tumors 2010; 2:e54] [page 155]
lymphoid infiltrate was highly suggestive of a
malignant lymphoma. The differential diagno-
sis for further classification included follicular
lymphoma,  mantle  cell  lymphoma,  small
lymph  ocytic lymphoma (SLL), and extranodal
marginal zone lymphoma of a MALT type. The
latter  was  favored  based  on  morphology.
Immuno  stains were performed for a definitive
classification  of  this  lesion.  Immunostains
showed  that  the  follicular  center  cells  were
CD10, bcl-6 (marker for follicular center cells)
positive but bcl-2 (marker for follicular lym-
phoma)  negative  (which  ruled  out  follicular
lymphoma). The interfollicular small lympho-
cytes were positive for CD20 (a B-cell marker)
and negative for CD3 (a T-cell marker), CD5
(marker for both mantle cell and small lympho-
cytic  lymphoma),  CD23  (marker  for  small
lymph  ocytic lymphoma), and bcl-1 (marker for
mantle cell lymphoma), which ruled out man-
tle  cell  lymphoma  and  small  lymphocytic
lymph  oma.  The  Ki67  immunostain  showed
that less than 10% of the lymphoma cells were
positive  (low  proliferation  rate).  Therefore,
this lymphoid lesion was classified as extran-
odal marginal zone B-cell lymphoma of a MALT
type. Figure 4 shows the immunostaining of
the sections. Imaging was positive for residual
disease in the prostatic fossa only. The patient
was  recommended  adjuvant  radiation  treat-
ment to the prostatic fossa for both his MALT
lymphoma and potentially positive margin of
his Gleason 8 prostate cancer. His prostatatic
fossa was treated to 6600 cGy, which was a suf-
ficient dose to treat both his MALT lymphoma
and  adjuvant  therapy  for  a  positive  prostate
cancer margin after radical prostatectomy. The
patient has remained disease-free for over one
year with an undetectable PSA.
Discussion
There is only one other case report in the lit-
erature  of  a  prostate  MALT  lymphoma  with
concurrent  adenocarcinoma,  in  which  the 
adenocarcinoma was treated according to the
Case Report
Figure 1. MALT lymphoma of the prostate.
A  monomorphic  lymphoid  population
infiltrates the prostate tissue. The lesional
lymphocytes are uniform and small in size,
some with clear cytoplasm. There are some
benign prostate glands in the upper right
corner  of  the  section.  (Hematoxylin-and-
eosin stain; low-power magnification.)
Figure 2. Adenocarcinoma of the prostate
(Gleason 3+5). Most of the neoplastic cells
form variable sized glands in an infiltrative
growth  pattern  (Gleason  score  3);  some
single  tumor  cells  are  also  present
(Gleason  score  5).  (Hematoxylin-and-
eosin stain; high-power magnification.)
Figure 3. Lympho-epithelial lesion charac-
teristic of MALT. (Hematoxylin-and-eosin
stain; high-power magnification.)
Figure 4. Immunostaining of the prostatic tissue.[page 156] [Rare Tumors 2010; 2:e54]
stage while the MALT lymphoma was managed
according to individual treatment strategies.
17
Because MALT lymphomas are characteristic  -
ally  indolent  and  prostatic  adenocarcinomas
are more aggressive in nature, therapy is tar-
geted  toward  treating  the  adenocarcinoma.
Unfortunately,  the  chronology  in  which  the
cancers appeared is unknown, but perhaps the
difference in their prognoses may give insight
into the etiology.  
The long, indolent course of MALT lymph  -
omas  might  suggest  that  the  disease  is  the
result of a chronic process. Typically, they arise
in extranodal sites that lack native lymphoid
tissue but acquire MALT in close association
with  chronic  inflammation  or  autoimmune
processes, like Sjogren’s syndrome and chron-
ic  sclerosing  sialadenitis.
20 They  arise  most
commonly in the stomach, orbit, thyroid, saliv  -
ary  glands,  breast,  lung,  skin,  and  bladder.
However, they have also been reported to occur
in the gallbladder, nasopharynx, and thymus.
21
MALT is known to develop in regions associat-
ed  with  infection  or  inflammation.  Gastric
MALT lymphoma is associated with H. pylori
infection,
22 cutaneous MALT is associated with
Borrelia  burgdorferi infection  in  Europe  but
not in the United States, orbital adnexal MALT
lymphoma is associated with Chlamydophila
psittaci,  and  intraocular  MALT  is  associated
with Toxoplasma gondii.
23 Even though there
have been specific infectious agents associat-
ed with MALT, not all MALT can be linked to a
specific  microbe.  The  genitourinary  tract  is
part  of  the  mucosal  immune  system,  and
includes  prostate-associated  lymphoid  tissue
(PALT). PALT consists of intra-epithelial leuko-
cytes (mostly T-cells) and lymphoid aggregates
below  the  epithelia,  which  constitute  suffi-
cient  machinery  for  cellular  and  humoral
immune responses.
24 The PALT contains some
native  B-cells,  and  thus  houses  an  entirely
local prostatic source of progenitor cells for the
development of MALT lymphoma.  
There has been discussion in the literature
that prostate MALT lymphoma may be associat-
ed with H. pylori infection, but eradication of
H. pylori is not yet a standard treatment for
MALT lymphoma of the prostate because the
role  of  infection  has  not  been  validated.
22
Previous case reports of urine cultures have
been negative and often there is no history of
acute  prostatitis  in  patients  with  the  dis-
ease.
15,16 However,  given  the  long  history  of
urin  ary  obstruction  in  four  out  of  six  case
reports  and  another  with  noted  prostatism,
chronic inflammation would seem likely to play
a significant role in the etiology of MALT lym-
phoma of the prostate. The unique composi-
tion of the prostate provides a suitable envi-
ronment  for  MALT  to  arise  from  normal
prostate-associated lymphoid tissue. It is noted
that  prostate  cancer  and  benign  prostatic
hyperplasia (BPH) can be associated with pro-
statitis.  There  are  some  investigators  who
hypothesize that inflammation may be linked
to  the  development  of  prostate  cancer.
Pathological  specimens  from  transurethral
resection of the prostate (TURP) and radical
prostectomy have been shown frequently to be
associated  with  inflammation.
25 Areas  of
inflammation show up the regulation of bcl-2.
26
It is still unknown if BPH and prostate cancer
promote or develop in response to inflamma-
tion. Thus it is difficult to assess if the two pri-
mary  cancers  occurred  in  a  synchronous  or
metachronous fashion. Did chronic inflamma-
tion  increase  the  risk  of  developing  both
prostate adenocarcinoma and MALT or did the
prostate  cancer  create  a  local  inflammatory
environment more likely to induce MALT trans-
formation  from  normal  prostate-associated
lymphoid tissue? MALT of the prostate is a rare
entity  and  concurrent  disease  is  even  rarer.
With such few cases reported in the literature,
while there are millions of men diagnosed with
BPH and prostate cancer annually, determin-
ing the sequence of events is likely impossible. 
It has been difficult to establish the precise
roles of infection (with one pathogen or multi-
ple) versus inflammation in instigating MALT
lymphoma of the prostate. MALT lymphomas
may also arise from more than one clonegen
adding even more complexity to the question
of  synchronous  versus  metachronous  occur-
rence.
27,28 The prostate is a site with the poten-
tial for such transformation but this is rare.
Nevertheless,  this  case  shows  that  MALT
lymph  oma  of  the  prostate  can  arise  concur-
rently with adenocarcinoma of the prostate.
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